Cellestia Biotech receives investment to advance therapies
SNGLR Capital AG, based in Zug, Switzerland, announces its first investment in Basel-based biotech company Cellestia Biotech. Cellestia was a Venture Leader China in 2018 and one of the TOP 100 Swiss Startups from 2016 to 2019.
SNGLR Capital AG, with its early-stage exponential technology venture capital fund, is very glad to join a great shareholder community and is pleased to support Cellestia on its further development.
“Our investment thesis focuses, among other things, on applications in the field of personal medicine with strong growth potential. We see these points very well supported by Cellestia. Above all, the advanced phase II study data allow an investment with less risk compared to other early-stage investment rounds,” said Dr. med Eszter Tanzcos Olver, Lead Partner Longevity SNGLR Capital.
“We were very impressed by the promising Phase I data with sign of clinical efficacy of the CB-103, a first-in-class small molecule targeted therapy with a novel mode of action and the efficiency of the Cellestia team. It is very exciting to contribute with our investment, to help many people who today have no treatment option with this new therapy tailored to the oncology profile of an individual patient,” said Klaus Kummermehr, CEO of SNGLR Capital.
“It is a great honor for us to welcome SNGLR Capital as new institutional investor, and we thank for the investment in our company. The additional capital will enable us to reach important milestones and to continue creating value for our shareholders,” said Gaudenz von Capeller, CFO of Cellestia Biotech AG.
About Cellestia Biotech AG
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has
advanced to Phase 2 successfully treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.
About SNGLR Capital AG
SNGLR is pronounced “singular” and expresses our drive and enthusiasm to work with singular, exponential technologies. SNGLR Capital AG is the venture capital entity within the SNGLR Group and is focused on investments in the sectors longevity and smart mobility/ smart cities, and lead exponential technologies such as AI or blockchain. SNGLR Group has two other entities, beside the Capital team and forms all together a unique business model:
SNGLR Digital, a team of skilled and diverse advisors & consultants with strong capabilities ranging from strategy to digital innovation, M&A, marketing and data analytics. The aim is to excel and help clients and startups solve the greatest challenges around exponential technologies.
SNGLR XLabs, Highly skilled IT Gurus & deep tech devs that build bespoke solutions for
clients as well as internal applications, leveraging the latest technologies (AI, blockchain,
Source: Press Release
BioVersys Announces First Subjects Dosed in Phase 1 Clinical...
Innovation in the fight against a creeping pandemic
Cellestia presented promising clinical data of its lead comp...
Monte Rosa Therapeutics Announces $96 Million Series B Finan...
BioVersys Announces CHF 19 Million Financing to Advance Nove...